BLOOD-COAGULATION

Improved understanding of the complex interrelated mechanisms that constitute haemostasis have provided new diagnostic and therapeutic options. Indeed, recent advances in DNA technology suggest that diagnosis at the molecular genetic level could soon be part of a 'routine' investigation of congenital haemostatic disorders. This update focuses on areas of recent development within haemostasis, the key role of the endothelium and platelets, the molecular basis of inherited bleeding disorders and the therapeutic use of genetically engineered proteins and assessment of fibrinolysis. The use of standards and quality assessment in haemostasis is also reviewed.